Medpace (NASDAQ:MEDP – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Monday, April 22nd. Analysts expect Medpace to post earnings of $2.45 per share for the quarter. Medpace has set its FY24 guidance at $10.18-10.87 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Monday, February 12th. The company reported $2.46 EPS for the quarter, topping the consensus estimate of $2.22 by $0.24. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The company had revenue of $498.40 million during the quarter, compared to the consensus estimate of $498.72 million. During the same period last year, the company earned $2.12 EPS. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. On average, analysts expect Medpace to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.
Medpace Stock Performance
NASDAQ MEDP opened at $372.00 on Friday. Medpace has a one year low of $185.43 and a one year high of $419.42. The stock has a 50-day moving average of $395.78 and a 200 day moving average of $319.96. The company has a market capitalization of $11.52 billion, a price-to-earnings ratio of 41.89, a PEG ratio of 2.02 and a beta of 1.38.
Analysts Set New Price Targets
Read Our Latest Analysis on Medpace
Insiders Place Their Bets
In other Medpace news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders have sold a total of 189,340 shares of company stock valued at $76,651,647 in the last quarter. 20.30% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Medpace
Several large investors have recently modified their holdings of MEDP. Altshuler Shaham Ltd bought a new position in Medpace in the 4th quarter valued at $27,000. Rockefeller Capital Management L.P. grew its position in Medpace by 361.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 143 shares of the company’s stock valued at $30,000 after acquiring an additional 112 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in Medpace in the 2nd quarter valued at $42,000. Bartlett & CO. Wealth Management LLC grew its position in Medpace by 133.3% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 175 shares of the company’s stock valued at $54,000 after acquiring an additional 100 shares during the last quarter. Finally, Stephens Inc. AR grew its position in Medpace by 121.4% in the 4th quarter. Stephens Inc. AR now owns 186 shares of the company’s stock valued at $57,000 after acquiring an additional 102 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Stories
- Five stocks we like better than Medpace
- Industrial Products Stocks Investing
- Comprehensive Analysis of PayPal Stock
- Compound Interest and Why It Matters When Investing
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.